-
Forbion’s portfolio company ARGENX has successfully been listed on the NASDAQ stock exchange
May 23, 2017Naarden, May 22, 2017 We are pleased to announce that our portfolio company argenx (Euronext Brussels: ARGX) has successfully...
0 -
Forbion invests in Prexton Therapeutics’ EUR 29 million Series B financing
February 7, 2017Forbion invests in Prexton Therapeutics’ EUR 29 million (USD 31 million) Series B financing Forbion & Seroba co-led funding,...
-
Forbion’s portfolio company Akarna Therapeutics Ltd acquired by Allergan plc
September 21, 2016Forbion’s portfolio company Akarna Therapeutics Ltd acquired by Allergan plc Allergan acquires Akarna to develop highly differentiated treatments for...
-
BioGeneration Ventures announces first close of its third fund
July 5, 2016BioGeneration Ventures announces first close of its third fund Providing fresh capital to innovative Dutch and other European Life...
-
Forbion closes third life sciences fund, FCF III
April 12, 2016Forbion closes third life sciences fund, FCF III, raising over $200m Investment focus on European, US & Canadian private...
-
Amgen acquires Forbion portfolio company Dezima Pharma
September 17, 2015Amgen acquires Forbion portfolio company Dezima Pharma Upfront payment of USD 300m plus up to USD 1.25bn in development...
-
Forbion announces the closing of FCF II Co-Invest Fund I at EUR 75M
September 10, 2015Forbion announces the closing of FCF II Co-invest Fund I at EUR 75M Naarden, The Netherlands, 10 September...
-
Forbion invests €36.6M
September 8, 2015Forbion invests in Sanifit’s €36.6M ($41M) Series C financing round Financing will advance Sanifit’s lead drug candidate through...
-
Forbion Announcement Promedior
September 1, 201531 August 2015 Forbion Announces – Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its...
-
Forbion announces that Pfizer acquires interest in its portfolio Company AM-Pharma
May 12, 2015Pfizer acquires minority interest in AM-Pharma; Secures option to acquire company. Option may be exercised based on Phase II...